Thyroid Cancers | Clinical

Tissue TMB Shows Potential as Biomarker of Response to Pembrolizumab in Thyroid Cancer

January 12, 2021

Patients with tissue tumor mutational burden-high solid tumors represent a subset of patients who could have a robust tumor response to the immune checkpoint inhibitor pembrolizumab as monotherapy, suggesting tTMB may be a novel and useful predictor of response in patients with previously treated recurrent or metastatic advanced solid tumors, including thyroid cancer.

VEGFR Targeting with Cabozantinib Achieves PFS Benefit in RAI-Refractory DTC

December 22, 2020

Cabozantinib demonstrated significant improvement in progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to 2 prior vascular endothelial growth factor receptor-targeted therapies compared with placebo, meeting the primary end point of the pivotal phase 3 COSMIC-311 clinical trial.

FDA Approves Pralsetinib for RET+ Thyroid Cancers

December 01, 2020

The FDA approved pralsetinib for the treatment of adult and pediatric patients who are 12 years old or older with advanced or metastatic RET-mutant medullary thyroid cancer and require systemic therapy.

Multiple Studies Provide Efficacy Results for Lenvatinib in Thyroid Cancer

November 27, 2020

Matthew Taylor, MD, reviewed the clinical trials supporting levantinib as a treatment option for a patient with thyroid cancer and discussed the option with a group of oncologists during a Targeted Oncology Case Base Peer Perspectives event.

Task Force Recommends Active Surveillance for Many Low-Risk Papillary Thyroid Microcarcinoma Patients

November 19, 2020

Active surveillance can be a safe and appropriate management strategy for patients with T1aN0M0 low-risk papillary thyroid microcarcinoma, though the decision to use the strategy requires multidisciplinary teams and patient input, according to a new report.